Fundz

Abeona Therapeutics to Acquire APT-1011 Assets from Ellodi Pharmaceuticals

PUBLIC · ABEONov 09, 2026

Acquiring Company

Abeona Therapeutics

Acquired Company

Ellodi Pharmaceuticals L.P

EnglandWilmingtonBiotechnologyHealth CareTherapeuticsBiotechnologyHealth CareTherapeuticsPharmaceutical

Description

On November 6, 2026, Abeona Therapeutics Inc. entered into an Asset Purchase Agreement with Ellodi Pharmaceuticals, L.P. to acquire substantially all assets related to the clinical-stage candidate APT-1011. This transaction is intended to advance the development of APT-1011 for treating eosinophilic esophagitis. The deal includes an issuance of common stock and potential future milestone payments based on regulatory approvals and sales.

Who to call at Abeona Therapeutics, and when

When Abeona Therapeutics changes hands, the new owners review vendors, systems and leadership. That is when the door opens.

  • An alert the day Abeona Therapeutics raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Abeona Therapeutics, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Abeona Therapeutics. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Abeona Therapeutics

Location

England, United Kingdom

About

Abeona Therapeutics Inc. is a cell and gene therapy company with proprietary adeno-associated virus (AAV)-based capsids.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Abeona Therapeutics makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Predictive Intelligence
Strategic

ML-powered predictions for Abeona Therapeutics's next move

Learn about Strategic plan

Frequently asked

Who acquired Ellodi Pharmaceuticals L.P?

Ellodi Pharmaceuticals L.P was acquired by Abeona Therapeutics, based in England. The deal was reported on November 9, 2026. Abeona Therapeutics Inc. is a cell and gene therapy company with proprietary adeno-associated virus (AAV)-based capsids. Abeona Therapeutics is publicly traded (ABEO) and operates in Biotechnology.

When did Abeona Therapeutics acquire Ellodi Pharmaceuticals L.P?

Abeona Therapeutics's acquisition of Ellodi Pharmaceuticals L.P was reported on November 9, 2026. On November 6, 2026, Abeona Therapeutics Inc. entered into an Asset Purchase Agreement with Ellodi Pharmaceuticals, L.P. to acquire substantially all assets related to the clinical-stage candidate APT-1011. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.

What does Ellodi Pharmaceuticals L.P do?

Ellodi Pharmaceuticals, L.P. is a pharmaceutical company dedicated to the development of innovative treatments for various medical conditions. It is privately held, operating in Biotechnology, and is based in Wilmington.

This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.